Cyntellect Wins $100K SBIR Phase I NSF Grant
Cyntellect of San Diego, Calif., said this week that it had won a $100,000 Small Business Innovation Research Phase I grant from the NSF. The grant will allow the subsidiary of Oncosis to run high-throughput functional proteomics studies in living cells using LEAP optoinjection and CALI-targeted protein inactivation. LEAP, which stands for Laser-Enabled Analysis and Processing, allows scientists to inject proteins into cells with a high-speed targeting laser. CALI, or chromophore-assisted laser activation, is used to inactivate proteins in cells.
EMBL and Partners Get €3.5M for TB Structural Proteomics
The European Molecular Biology Laboratory outstation in Hamburg, Germany, said this week that along with its six academic and industrial partners it had received a €3.5 million ($4 million) grant from the German Federal Ministry of Education and Research to study the structure of proteins from Mycobacterium tuberculosis by X-ray crystallography and NMR. In addition to research, the collaborating groups plan to use the money to build new infrastructure, including a high-throughput crystallization facility at EMBL.
Canadian Government Earmarks $CA65M for Applied Genomics and Proteomics
The Canadian government will provide $CA65 million ($48.2 million) for an applied genomics and proteomics competition, Canadian Industry Minister Allan Rock said on Monday at the BIO 2003 meeting in Washington, DC. Canadian researchers can submit proposals for research that will have a near-term impact on human health in the area of prediction, prevention, or treatment. Genome Canada will review proposals and choose the winning projects by April 2004.
GWC Receives $100K Grant from NSF
GWC Technologies of Madison, Wis. said it had received $99,724 from the NSF to further develop its FT-SPR systems, which combines SPR techniques with FTIR spectrometry. The technique enables label-free detection of biomolecular samples in parallel and was developed through a partnership between GWC and Robert Corn, a researcher at the University of Wisconsin-Madison. GWC says it will use the money to make FT-SPR more widely available, and to develop the instrument’s ability to detect more interactions.
Inpharmatica Receives Milestone Payment from Serono
Inpharmatica of London said last week that it had received its first payment for a secreted protein it delivered to its Swiss partner Serono.
The protein results from a research collaboration the two companies started in July 2001 to develop novel therapeutic proteins and drug targets. Inpharmatica uses its PharmaCarta chemogenomics informatics platform to identify protein candidates. It has so far delivered over 100 secreted proteins to Serono, but the protein in question is the first to reach Serono’s “developmental milestones.” If any protein found by the bioinformatics company reaches the market, it stands to receive further payment in the form of royalties.
Advanced Life Sciences Wins SBIR NIH Grant to Combat Protein Aggregation Diseases
Advanced Life Sciences of Woodridge, Ill. said this week that it had won a Small Business Innovation Research Grant from the NIH to develop treatments for a variety of protein aggregation diseases, including Alzheimer’s and Down’s Syndrome, using proteomics.
The research, to be conducted in collaboration with Argonne National Laboratory, will focus on the search for natural and synthetic small molecules that can interfere with protein-protein interactions and thus prevent or break up fibrils via protein stabilization or disassociation.
Medical University of South Carolina Gets $4M from Lottery for Proteomics Center
The Proteomics Research Center at the Medical University of South Carolina has received $4 million in matching funds from the South Carolina Lottery Center of Economic Excellence. Last fall, the center won a $15 million grant from the National Heart, Lung, and Blood Institute.
Bio-Rad and APAF Renew Technology Development Partnership
Bio-Rad Laboratories and the Australian Proteome Analysis Facility in Sydney said last week that they have renewed their existing technology development partnership for another three years.
In exchange for research funding, Bio-Rad will get early access to new proteomics technologies developed at APAF, according to Tom Slyker, Bio-Rad’s proteomics program manager.